ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

MWX203

A development code. Also written as “MWX203 S1”, “MWX203 S2” and “MWX203 S3”.

Its studies are mostly in Dyslipidemias, led by Lepu Medical.

Furthest: phase 2, since Sep 1, 20262 company-led studies, 2 open or runningNext primary completion: Feb 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Lepu Medical22 open or runningphase 2since Sep 1, 2026Aug 24, 2026Feb 2028phase 2 · NCT07803822

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 24, 2026First study: phase 1 study in Healthy VolunteersFirst studyNCT07799025 · 54 enrolled · China
  2. Sep 1, 2026Phase 2 study in Mixed DyslipidemiaPhase 2 reachedNCT07803822 · 216 planned · China

Ahead

  1. Feb 2028Primary completion: phase 2 study in Mixed DyslipidemiaNCT07803822

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07803822Mixed Dyslipidemia · China2RecruitingFeb 2028216
NCT07799025Healthy Volunteers · China1Active, not recruitingMar 7, 202654

How it is read

Names in the registry

  • “MWX203”, 1 entry
  • “MWX203 S1”, 1 entry
  • “MWX203 S2”, 1 entry
  • “MWX203 S3”, 1 entry
  • “MWX203 S4”, 1 entry

Codes read as this program: MWX203.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.